IP Library Granted Patent US 7,910,743
Granted Patent B2
US 7,910,743 · App. 12/469,603 · Granted Mar 22, 2011

Compounds, compositions and methods

Assignee: Cytokinetics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,910,743
App. No.
12/469,603
Granted
Mar 22, 2011
Kind
B2
Abstract

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Claims (72)

1. At least one chemical entity chosen from compounds of Formula I

and pharmaceutically acceptable salts, wherein

T is —O—;

W, X, Y, and Z are —C═;

R 1 is optionally substituted alkyl;

R 2 is optionally substituted pyridin-3-yl;

R 3 is hydrogen;

R 4 is fluoro; and

R 5 is hydrogen;

R 6 and R 7 are hydrogen; and

R 13 is hydrogen.

2. At least one chemical entity of claim 1 wherein R 1 is substituted lower alkyl optionally substituted with one or two groups chosen from optionally substituted alkoxy and optionally substituted amino.

3. At least one chemical entity of claim 1 where R 1 is selected from 1-methoxypropan-2-yl, (1-acetamidocyclopentyl)methyl, 2-acetamido-2-methylprop-1-yl, 2-(methoxycarbonylamino)eth-1-yl, 2-(tert-butoxycarbonyl(methyl)amino)eth-1-yl, 1-(methoxycarbonyl(methyl)amino)propan-2-yl, 1-(tert-butoxycarbonyl(methyl)amino)propan-2-yl, 2-acetamidoeth-1-yl, 2-(N-methylacetamido)eth-1-yl, 1-(N-methylacetamido)propan-2-yl, 2-(N,N-dimethylsulfamoylamino)eth-1-yl, 2-((N,N-dimethylsulfamoyl)(methyl)amino)eth-1-yl, 1-((N,N-dimethylsulfamoyl)(methyl)amino)propan-2-yl, 2-(ethylsulfonamido)eth-1-yl, 2-(N-methylethylsulfonamido)eth-1-yl, 1-(N-methylethylsulfonamido)propan-2-yl, 1-(N-methylpropan-2-ylsulfonamido)propan-2-yl, 2-(N-methylpropan-2-ylsulfonamido)eth-1-yl, 2-(2-cyano-1,3,3-trimethylguanidino)eth-1-yl, 2-(methylamino)eth-1-yl, 5-methyl-1,1-dioxo-1λ 6 -[1,2,5]thiadiazolidin-2-yl-ethyl; 5-methyl-1,1-dioxo-1λ 6 -[1,2,5]thiadiazolidin-3-yl-methyl; 2,6-dimethyl-1,1-dioxo-1λ 6 -[1,2,6]thiadiazinan-4-yl-methyl,

4. At least one chemical entity of claim 3 where R 1 is selected from 2-(methoxycarbonylamino)eth-1-yl, 1-(methoxycarbonyl(methyl)amino)propan-2-yl, 2-acetamido-2-methylprop-1-yl, 2-(N,N-dimethylsulfamoylamino)eth-1-yl, 2-((N,N-dimethylsulfamoyl)(methyl)amino)eth-1-yl, 1-((N,N-dimethylsulfamoyl)(methyl)amino)propan-2-yl, 2-(ethylsulfonamido)eth-1-yl, 2-(N-methylethylsulfonamido)eth-1-yl, 1-(N-methylethylsulfonamido)propan-2-yl, 1-(N-methylpropan-2-ylsulfonamido)propan-2-yl, and 2-(N-methylpropan-2-ylsulfonamido)eth-1-yl.

5. At least one chemical entity of claim 1 wherein R 2 is pyridin-3-yl optionally substituted with lower alkyl.

6. At least one chemical entity of claim 1 wherein the compound of Formula I is chosen from

N-[5-fluoro-3-(2-methoxy-isopropoxy)phenyl][(6-methoxy(3-pyridyl))amino]carboxamide;

N-[5-fluoro-3-(2-methoxy-isopropoxy)phenyl](3-pyridylamino)carboxamide;

[(6-methoxy(3-pyridyl))amino]-N-[3-(methylethoxy)phenyl]carboxamide;

N-[({5-fluoro-3-[(N-(3-pyridyl)carbamoyl)amino]phenoxy}methyl)cyclopentyl]acetamide;

N-(2-{5-fluoro-3-[(N-(3-pyridyl)carbamoyl)amino]phenoxy}-tert-butyl)acetamide;

N-{2-[5-fluoro-3-({N-[6-(trifluoromethyl)(3-pyridyl)]carbamoyl}amino)phenoxy]-tert-butyl}acetamide;

N-[2-(5-fluoro-3-{[N-(6-methoxy(3-pyridyl))carbamoyl]amino}phenoxy)-tert-butyl]acetamide;

N-({[3-fluoro-5-({[6-(trifluoromethyl)(3-pyridyl)]amino}carbonylamino)phenoxy]methyl}cyclopentyl)acetamide;

N-{[(3-fluoro-5-{[(6-methoxy(3-pyridyl))amino]carbonylamino}phenoxy)methyl]cyclopentyl}acetamide;

N-{5-fluoro-3-[2-(methoxycarbonylamino)ethoxy]phenyl}(3-pyridylamino)carboxamide;

N-(2-{3-fluoro-5-[(3-pyridylamino)carbonylamino]phenoxy}ethyl)acetamide;

N-[3-(2-{[(dimethylamino)sulfonyl]amino}ethoxy)-5-fluorophenyl](3-pyridylamino)carboxamide;

N-(3-{2-[(ethylsulfonyl)amino]ethoxy}-5-fluorophenyl)(3-pyridylamino)carboxamide;

N-(2-{3-fluoro-5-[(3-pyridylamino)carbonylamino]phenoxy}ethyl)methoxy-N-methylcarboxamide;

N-(2-{3-fluoro-5-[(3-pyridylamino)carbonylamino]phenoxy}ethyl)-N-methylacetamide;

N-[3-(2-{[(dimethylamino)sulfonyl]methylamino}ethoxy)-5-fluorophenyl](3-pyridylamino)carboxamide;

N-(3-{2-[(ethylsulfonyl)methylamino]ethoxy}-5-fluorophenyl)(3-pyridylamino)carboxamide;

N-[3-(2-{[(1Z)-1-(dimethylamino)-2-cyano-2-azavinyl]methylamino}ethoxy)-5-fluorophenyl](3-pyridylamino)carboxamide;

N-[3-((1R)-2-{[dimethylamino)sulfonyl]methylamino}-isopropoxy)-5-fluorophenyl](3-pyridylamino)carboxamide;

N-(3-{(1R)-2-[(ethylsulfonyl)methylamino]-isopropoxy}-5-fluorophenyl)(3-pyridylamino)carboxamide;

N-(3-{(1R)-2-[(tert-butoxy)-N-methylcarbonylamino]-isopropoxy}-5-fluorophenyl)(3-pyridylamino)carboxamide;

N-{3-[(1R)-2-(methoxy-N-methylcarbonylamino)-isopropoxy]-5-fluorophenyl}(3-pyridylamino)carboxamide;

N-{3-[(1R)-1-methyl-2-(methylamino)ethoxy]-5-fluorophenyl}(3-pyridylamino)carboxamide;

N-[3-((1S)-2-{[dimethylamino)sulfonyl]methylamino}-isopropoxy)-5-fluorophenyl]-3-pyridylamino)carboxamide;

N-(3-{(1S)-2-[(ethylsulfonyl)methylamino]-isopropoxy}-5-fluorophenyl)(3-pyridylamino)carboxamide;

N-((2S)-2-{3-fluoro-5-[(3-pyridylamino)carbonylamino]phenoxy}propyl)methoxy-N-methylcarboxamide;

N-((2S)-2-{3-fluoro-5-[(3-pyridylamino)carbonylamino]phenoxy}propyl)-N-methylacetamide;

N-[3-(2-{[(1E)-1-(dimethylamino)-2-cyano-2-azavinyl]methylamino}(1S)-isopropoxy)-5-fluorophenyl](3-pyridylamino)carboxamide;

N-[3-((1S)-1-methyl-2-{methyl[(methylethyl)sulfonyl]amino}ethoxy)-5-fluorophenyl](3-pyridylamino)carboxamide;

N-((2R)-2-{3-fluoro-5-[(3-pyridylamino)carbonylamino]phenoxy}propyl)-N-methylacetamide;

N-[3-(2-{[(1E)-1-(dimethylamino)-2-cyano-2-azavinyl]methylamino}(1R)-isopropoxy)-5-fluorophenyl](3-pyridylamino)carboxamide;

N-[3-(2-{[(dimethylamino)sulfonyl]methylamino}ethoxy)-5-fluorophenyl][(6-methyl(3-pyridyl))amino]carboxamide;

N-(3-{2-[(ethylsulfonyl)methylamino]ethoxy}-5-fluorophenyl)[(6-methyl(3-pyridyl))amino]carboxamide;

N-[5-fluoro-3-(2-{methyl[(methylethyl)sulfonyl]amino}ethoxy)phenyl][(6-methyl(3-pyridyl))amino]carboxamide;

N-[3-(2-{[(dimethylamino)sulfonyl]methylamino}ethoxy)-5-fluorophenyl][(4-fluorophenyl)amino]carboxamide;

N-(3-{2-[(ethylsulfonyl)methylamino]ethoxy}-5-fluorophenyl)[(4-fluorophenyl)amino]carboxamide;

N-[5-fluoro-3-(2-{methyl[(methylethyl)sulfonyl]amino}ethoxy)phenyl][(4-fluorophenyl)amino]carboxamide;

N-(3-{(1R)-2-[(tert-butoxy)-N-methylcarbonylamino]-isopropoxy}-5-fluorophenyl)[(6-methyl(3-pyridyl))amino]carboxamide;

N-[3-((1R)-2-{[(dimethylamino)sulfonyl]methylamino}-isopropoxy)-5-fluorophenyl][(6-methyl(3-pyridyl))amino]carboxamide;

N-(3-{(1R)-2-[(ethylsulfonyl)methylamino]-isopropoxy}-5-fluorophenyl)[(6-methyl(3-pyridyl))amino]carboxamide;

N-[3-((1R)-1-methyl-2-{methyl[(methylethyl)sulfonyl]amino}ethoxy)-5-fluorophenyl][(6-methyl(3-pyridyl))amino]carboxamide;

N-{3-[(1R)-2-(methoxy-N-methylcarbonylamino)-isopropoxy]-5-fluorophenyl}[(6-methyl(3-pyridyl))amino]carboxamide;

N-[3-((1S)-2-{[(dimethylamino)sulfonyl]methylamino}-isopropoxy)-5-fluorophenyl][(6-methyl(3-pyridyl))amino]carboxamide;

N-(3-{(1S)-2-[(ethylsulfonyl)methylamino]-isopropoxy}-5-fluorophenyl)[(6-methyl(3-pyridyl))amino]carboxamide;

N-[3-((1S)-1-methyl-2-{methyl[(methylethyl)sulfonyl]amino}ethoxy)-5-fluorophenyl][(6-methyl(3-pyridyl))amino]carboxamide;

N-[(2S)-2-(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}phenoxy)propyl]methoxy-N-methylcarboxamide;

N-[(2S)-2-(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}phenoxy)propyl]-N-methylacetamide;

N-[3-(2-{[(1E)-1-(dimethylamino)-2-cyano-2-azavinyl]methylamino}(1S)-isopropoxy)-5-fluorophenyl][(6-methyl(3-pyridyl))amino]carboxamide;

N-{3-[2-{[(dimethylamino)sulfonyl]methylamino}-1-({[(dimethylamino)sulfonyl]methylamino}methyl)ethoxy]-5-fluorophenyl}(3-pyridylamino)carboxamide;

N-{3-[2-{[(dimethylamino)sulfonyl]methylamino}-1-({[(dimethylamino)sulfonyl]methylamino}methyl)ethoxy]-5-fluorophenyl}[(6-methyl(3-pyridyl))amino]carboxamide;

N-{5-fluoro-3-[2-(5-methyl-1,1-dioxo(1,2,5-thiadiazolidin-2-yl))ethoxy]phenyl}(3-pyridylamino)carboxamide;

N-{5-fluoro-3-[2-(5-methyl-1,1-dioxo(1,2,5-thiadiazolidin-2-yl))ethoxy]phenyl}[(6-methyl(3-pyridyl))amino]carboxamide;

N-{3-[(2,5-dimethyl-1,1-dioxo(1,2,5-thiadiazolidin-3-yl))methoxy]-5-fluorophenyl}(3-pyridylamino)carboxamide; and

N-{3-[(2,5-dimethyl-1,1-dioxo(1,2,5-thiadiazolidin-3-yl))methoxy]-5-fluorophenyl}[(6-methyl(3-pyridyl))amino]carboxamide.

7. A pharmaceutical composition comprising a pharmaceutically acceptable excipient or adjuvant and at least one chemical entity of claim 1 .

8. The pharmaceutical composition of claim 7 wherein the composition is formulated in a form chosen from injectable fluids, aerosols, tablets, pills, capsules, syrups, creams, gels, and transdermal patches.

Continuity (4)
Division 11498986 · Aug 4, 2006
Provisional Application 60705848 · Aug 4, 2005
Provisional Application 60751123 · Dec 16, 2005
Related Publication 20090324511A1 · Dec 31, 2009